Sana Biotechnology will present at BofA Securities 2022

Sana Biotechnology will present at BofA Securities 2022

SEATTLE, May 4, 2022 (GLOBE NEWSWIRE) – Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on the creation and supply of engineered cells as medicines, announced today that it will webcast its presentation at the BofA Securities conference. 2022 Healthcare Wednesday May 11, 2022 at 3:20 pm PT. The presentation will feature a company overview and update from Steve Harr, Sana’s President and CEO.

The webcast will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replica of the presentation will be available at the same venue for 30 days following the conference.

About Healthy Biotechnology
Sana Biotechnology, Inc. focuses on creating and delivering engineered cells as medicines for patients. We share a vision to repair and control genes, replace missing or damaged cells, and make our therapies widely available to patients. We are a passionate group of people who work together to create an enduring company that changes the way the world treats disease. Sana has operations in Seattle, Cambridge, South San Francisco and Rochester. For more information on Sana biotechnology, visit https://sana.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company”, “we”, “us” or “our”) under federal securities laws, including those relating to the vision of the Company; and the Company’s participation in the BofA Securities 2022 Healthcare Conference; and the subject of the Company’s presentation at that conference. All statements other than statements of historical facts contained in this press release, including but not limited to statements regarding the Company’s strategy, expectations, cash flow and future financial condition, future operations and prospects, are statements forecast. In some cases, it is possible to identify forward-looking statements based on terminology such as “aim”, “anticipate”, “presuppose”, “believe”, “contemplate”, “continue”, “might”, “plan”, “due,” “estimate”, “expect”, “goal”, “mean”, “may”, “goal”, “plan”, “positioned”, “potential”, “predict”, “seek”, “should”, “target “,” will “,” would “and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections on future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the material uncertainties in these forward-looking statements, you should not rely on forward-looking statements as a forecast of future events. These statements are subject to risks and uncertainties that could materially vary actual results, including but not limited to drug development risks such as those associated with initiation, cost, timing, advancement and results of the Company’s current and future activities, research and development programs, preclinical and clinical studies, as well as the economic, market and social disturbances due to the ongoing public health crisis caused by COVID-19. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K dated March 16, 2022 Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements for any reason.

Investor and media relations:
Nicole Keith
investor.relations@sana.com
media@sana.com

.

Leave a Comment

Your email address will not be published.